425: Horizon Space II Adds Independent Directors for SL Bio Merger

Horizon Space Acquisition II Corp. supplements its proxy statement by adding two independent director nominees for the combined entity with SL BIO Ltd.

Summary

• Horizon Space Acquisition II Corp. (HSPT) filed a Form 8-K to supplement its definitive proxy statement for the proposed business combination with SL BIO Ltd.
• Two new independent director nominees, Joseph Levinson and Qian (Hebe) Xu, will be added to the board of SL Science Holding Limited (PubCo) following the Business Combination.
• Joseph Levinson has over 25 years of experience in cross-border issues for U.S.-listed foreign companies and accounting, holding a United States Certified Public Accountant license.
• Qian (Hebe) Xu has over 15 years of experience in financial markets, specializing in US-China cross-border transactions, and currently serves as an independent director for HSPT and Hongli Group Inc.
• Neither Mr. Levinson nor Ms. Xu will serve as a member of PubCo's board committees.
• The beneficial ownership table for PubCo Ordinary Shares immediately following the Business Combination has been updated to reflect the new nominees.
• William Wang Ching-Dong is expected to beneficially own 333,832,129 PubCo Ordinary Shares, representing 58.9% of PubCo Voting Power in the no redemption scenario and 59.6% in the maximum redemption scenario.
• Qian (Hebe) Xu will beneficially own 20,000 PubCo Ordinary Shares, representing less than 1% of PubCo Voting Power.
• There are no changes to the Business Combination Meeting schedule, including the meeting time (February 12, 2026, 9:00 a.m. Eastern Time), redemption deadline (February 10, 2026, 5:00 p.m. Eastern Time), location, record date (December 29, 2025), purpose, or any of the proposals.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive, procedural update. The addition of experienced independent directors strengthens corporate governance, which is generally well-received by investors, though it does not impact immediate financial performance.

Positives

• The addition of two experienced independent directors, Joseph Levinson and Qian (Hebe) Xu, enhances corporate governance for the combined entity.
• Joseph Levinson brings significant accounting and public company experience, including a CPA license and prior independent directorships at Robo.ai Inc. and China Liberal Education Holdings Ltd.
• Qian (Hebe) Xu brings extensive financial markets and US-China cross-border transaction expertise, having served as an independent director for HSPT and Hongli Group Inc.

Risks

• SL Bio's or the combined company's limited operating history.
• The ability of SL Bio or the combined company to identify and integrate acquisitions.
• General economic and market conditions impacting demand for the products of SL Bio or the combined company.
• The inability to complete the proposed Business Combination.
• The inability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, the amount of cash available following any redemptions by HSPT's shareholders.
• The ability to meet stock exchange listing standards following the consummation of the proposed Business Combination.
• Costs related to the proposed Business Combination.
• The possibility that the proposed Business Combination does not close, including due to the failure to receive required security holder approvals, or the failure of other closing conditions.

Future Outlook

The combined entity, SL Science Holding Limited (PubCo), expects its executive compensation program to reflect SL Bio's compensation policies and philosophies, as they may be modified and updated. Decisions regarding executive officer compensation will be made by PubCo's compensation committee. Non-executive independent directors will be entitled to compensation commensurate with their duties and experience, including annual or monthly cash retainers, reimbursement of reasonable expenses, and potential equity-based awards pursuant to an equity compensation plan to be adopted following the Business Combination.

Industry Context

StockSavvy.ai notes that the addition of independent directors is a standard practice in SPAC business combinations as companies transition to public status, aiming to strengthen corporate governance and meet listing requirements. The emphasis on cross-border experience reflects the global nature of many SPAC targets and the increasing scrutiny on governance for foreign-domiciled entities listing in the U.S.

Comparison to Industry Standards

• The appointment of independent directors with significant accounting, public company, and financial markets experience (Joseph Levinson, CPA, and Qian (Hebe) Xu, investment banking background) aligns with best practices for public company boards, similar to those seen in established Nasdaq-listed firms.
• The structure of director compensation, including cash retainers and equity-based awards, is a common industry standard for attracting and retaining qualified independent directors in publicly traded companies.
• The beneficial ownership structure, with a significant portion held by the CEO through related entities, is not uncommon in founder-led companies, but the addition of independent oversight helps balance control.

Management Changes

Corporate Governance

Related Party Transactions

• William Wang's equity interest in PubCo will be beneficially owned through SL Link Holding Ltd., a company owned equally by Mr. Wang and his spouse.
• William Wang's equity interest in PubCo will also be beneficially owned through SL Link Co., Ltd., a company controlled by Mr. Wang.
• On January 5, 2026, SL Link Co., Ltd. (controlled by Mr. Wang) entered into a securities transfer agreement with an individual shareholder of SL Bio, purchasing 30,000 ordinary shares of SL Bio at US$66.67 per share.

Stakeholder Impact

• Shareholders: The addition of experienced independent directors may be viewed positively, enhancing governance and potentially investor confidence. The updated beneficial ownership provides clarity on control.
• Management: The new board structure and compensation policies will define their oversight and incentives.
• Employees: No direct impact mentioned, but a stable governance structure can indirectly benefit employees.

Next Steps

• Shareholders to vote at the Business Combination Meeting on February 12, 2026.
• Consummation of the Business Combination between HSPT and SL Bio.
• Adoption of an equity compensation plan by PubCo following the Business Combination.
• PubCo's compensation committee to make decisions regarding executive officer compensation.

Key Dates

Recommendation

This filing primarily provides a procedural update regarding the addition of independent director nominees and an updated beneficial ownership table for the upcoming business combination. While the enhancement of corporate governance through experienced independent directors is a positive, it does not present new financial performance data or strategic shifts that would warrant a change in investment recommendation. Investors should hold their position pending the outcome of the business combination and further operational details of the combined entity.

Keywords

SPAC, Business Combination, Merger, Independent Director, Corporate Governance, SEC Filing, Form 8-K, Horizon Space Acquisition II Corp., SL BIO Ltd., PubCo, Nasdaq, Proxy Statement, Beneficial Ownership